UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors

Investigational new drugs, 2013-06, Vol.31 (3), p.751-759

2013

Link zum Volltext

Verfügbarkeit prüfen

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Nature communications, 2016-08, Vol.7 (1), p.12609-12609, Article 12609

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

Targeted oncology, 2019-02, Vol.14 (1), p.67-74

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-01, Vol.11 (2), p.703-711

2005

Link zum Volltext

Verfügbarkeit prüfen

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

Clinical cancer research, 2011-11, Vol.17 (22), p.7156-7163

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

Targeted oncology, 2019-02, Vol.14 (1), p.43-55

2019

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis of Irinotecan‐Induced Diarrhea with Neomycin and Potential Role for UGT1A128 Genotype Screening: A Double‐Blind, Randomized, Placebo‐Controlled Study

The oncologist (Dayton, Ohio), 2006-09, Vol.11 (8), p.944-954

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

Journal of clinical oncology, 2009-10, Vol.27 (30), p.5094-5101

2009

Link zum Volltext

Verfügbarkeit prüfen

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

Investigational new drugs, 2011-10, Vol.29 (5), p.953-962

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Clinical cancer research, 2014-09, Vol.20 (18), p.4776-4783

2014

Link zum Volltext

Verfügbarkeit prüfen

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

European journal of cancer (1990), 2010-11, Vol.46 (16), p.3016-3021

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Cancer chemotherapy and pharmacology, 2016-12, Vol.78 (6), p.1185-1197

2016

Link zum Volltext

Verfügbarkeit prüfen

Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia

Journal of clinical oncology, 2007-07, Vol.25 (19), p.2719-2726

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2014-08, Vol.32 (4), p.670-681

2014

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials

The oncologist (Dayton, Ohio), 2013-03, Vol.18 (3), p.323-329

2013

Link zum Volltext

Verfügbarkeit prüfen

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

Clinical cancer research, 2015-05, Vol.21 (10), p.2297-2304

2015

Link zum Volltext

Verfügbarkeit prüfen

Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation

Psycho-oncology (Chichester, England), 2018-01, Vol.27 (1), p.163-170

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors

Journal of clinical oncology, 2009-09, Vol.27 (25), p.4169-4176

2009

Link zum Volltext

Verfügbarkeit prüfen

Self‐reported quality of life and hope in phase‐I trial participants: An observational prospective cohort study

European journal of cancer care, 2018-11, Vol.27 (6), p.e12908-n/a

2018

Link zum Volltext

Verfügbarkeit prüfen

Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2010-02, Vol.16 (1), p.59-61

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Clinical cancer research, 2005-02, Vol.11 (4), p.1504-1511

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors

Clinical cancer research, 2003-09, Vol.9 (11), p.4101-4107

2003

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment

Anti-cancer drugs, 2013-02, Vol.24 (2), p.204-211

2013

Link zum Volltext

Verfügbarkeit prüfen

Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study

European journal of cancer (1990), 2010-01, Vol.46 (2), p.266-269

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(51)
Science & Technology
(47)
Middle Aged
(46)
Aged
(45)
Life Sciences & Biomedicine
(45)
Male
(45)
Female
(44)
Oncology
(44)
Biological And Medical Sciences
(28)
Medical Sciences
(28)
Neoplasms - Drug Therapy
(28)
Pharmacology. Drug Treatments
(25)
Antineoplastic Agents
(23)
Chemotherapy
(18)
Maximum Tolerated Dose
(18)
Antineoplastic Agents - Pharmacokinetics
(17)
Camptothecin - Analogs & Derivatives
(17)
Antineoplastic Agents - Administration & Dosage
(15)
Dose-Response Relationship, Drug
(15)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

Prophylaxis of Irinotecan‐Induced Diarrhea with Neomycin and Potential Role for UGT1A128 Genotype Screening: A Double‐Blind, Randomized, Placebo‐Controlled Study

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors

Self‐reported quality of life and hope in phase‐I trial participants: An observational prospective cohort study

Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment

Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study

Aktive Filter

Suchergebnisse filtern